AQST
Aquestive Therapeutics Inc
4.40$
-4.1%
vs. previous close
Closing price · As of: Oct 1, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2005 | 2006 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 18.7% | 61.3% | 59.2% | 65.3% | 85.4% | 87.0% | 71.0% | 76.2% | 69.9% | 71.3% | 87.0% | 93.0% | |
| 10.8% | 56.1% | 23.4% | 40.3% | 69.8% | 62.9% | 50.6% | 45.2% | 47.8% | 41.6% | 70.5% | 75.5% | |
| – | 56.1% | 23.4% | 40.3% | 69.8% | 62.9% | 50.6% | 45.2% | 47.8% | 41.6% | 70.5% | 75.5% | |
| 1.6% | 2.8% | 27.5% | 14.3% | 7.5% | 16.7% | 11.1% | 19.6% | 8.2% | 14.8% | 7.2% | 11.1% | |
| 5.4% | 1.7% | 7.3% | 9.3% | 6.3% | 3.6% | 3.9% | 6.5% | 10.1% | 11.8% | 6.0% | 3.8% | |
| 61.9% | 31.5% | 38.4% | 31.2% | 14.1% | 12.4% | 10.9% | 8.2% | 13.8% | – | – | – | |
| – | – | – | – | – | 0.4% | – | – | – | – | – | – | |
| 15.4% | 6.1% | 0.8% | 0.6% | 0.2% | 0.2% | 0.2% | 0.1% | 2.5% | 2.2% | – | – | |
| 62.1% | 7.0% | 144.6% | 161.5% | 88.4% | 107.8% | 177.1% | 232.5% | 307.7% | 285.5% | 159.3% | 121.0% | |
| 13.9% | 6.7% | 27.4% | 35.6% | 37.9% | 23.6% | 33.6% | 35.4% | 69.3% | 31.9% | 18.6% | 29.7% | |
| 2.3% | – | 98.1% | 0.8% | 5.3% | – | 5.3% | 4.7% | 33.2% | 0.7% | 0.5% | 7.2% | |
| 10.1% | 4.0% | 16.9% | 22.3% | 23.5% | 15.6% | 11.3% | 13.4% | 17.4% | 15.5% | 10.1% | 18.6% | |
| 48.1% | – | 98.1% | 105.5% | 49.1% | 76.9% | 54.6% | 83.2% | 58.6% | 47.9% | 32.0% | 17.2% | |
| 37.9% | 93.0% | -44.6% | -61.5% | 11.6% | -7.8% | -77.1% | -132.5% | -207.7% | -185.5% | -59.3% | -21.0% | |
| -96.2% | -90.5% | -275.9% | -278.5% | -70.7% | -166.3% | -296.2% | -414.2% | -545.3% | -555.7% | -358.1% | -278.6% | |
| – | – | 62.2% | 46.4% | 23.9% | 32.3% | 53.5% | 61.4% | 85.4% | 106.7% | 85.5% | 76.0% |
Data as of: October 1, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.